ArticleClinical ophthalmology (Auckland, N.Z.)2021
Intense Pulsed Plus Low-Level Light Therapy in Meibomian Gland Dysfunction.
Article in Clinical ophthalmology (Auckland, N.Z.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: A meta-analysis and systematic review.Indian journal of ophthalmology · 2023Pooled it
- Safety and efficacy of a novel intense pulsed light system in patients with meibomian gland dysfunction: a randomized, double-masked, intra-individual controlled study.International ophthalmology · 2025Trial
- A randomized controlled study evaluating outcomes of intense pulsed light and low-level light therapy for treating meibomian gland dysfunction and evaporative dry eye.Indian journal of ophthalmology · 2023Trial
- Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Cataract Surgery: A Prospective Double-Masked Randomized Controlled Clinical Trial.Ophthalmology and therapy · 2025Article
- Article
- Serial Sessions of a Novel Low-Level Light Therapy Device for Home Treatment of Dry Eye Disease.Ophthalmology and therapy · 2023Article
- Intense pulsed light-based treatment for the improvement of symptoms in glaucoma patients treated with hypotensive eye drops.Eye and vision (London, England) · 2022Article
- Low-Level Light Therapy in Association with Intense Pulsed Light for Meibomian Gland Dysfunction.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Eyelid Warming Devices: Safety, Efficacy, and Place in Therapy.Clinical optometry · 2022Review
- Dry eye disease and tear film assessment through a novel non-invasive ocular surface analyzer: The OSA protocol.Frontiers in medicine · 2022Article
- Pulsed Light Therapy in the Management of Dry Eye Disease: Current Perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Current practices and considerations in intense pulsed light therapy for meibomian gland dysfunction.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyse the clinical outcome in patients with meibomian gland dysfunction (MGD) who underwent intense pulsed light (IPL) plus low-level light therapy (LLL). MATERIALS AND
methodsThe prospective non-comparative study included identified by MGD patients with altered interferometry and lower loss area of the meibomian glands (LAMG), who underwent IPL plus LLL, between July 2020 and August 2020. A multimodal assessment was performed before, 2-3 weeks, and 6 months after treatment. The main outcome was lipid layer thickness (LLT) and the secondary outcomes were the ocular surface disease index (OSDI) score, presence of corneal fluorescein staining (CFS), blink rate (BR), Schirmer test (ST), tear meniscus height (TMH), tear osmolarity (OSM), non-invasive break-up time (NIBUT) and LAMG.
resultsThis study included 62 eyes of 31 patients, 61.3% female, with a mean age of 66.94±9.08 years at the time of IPL plus LLL treatment. LLT (<0.001) grades improved 6 months after treatment. The mean OSDI score improved (p<0.001) from 45.02±21.17 (severe symptoms) to 22.35±17.68 (moderate symptoms) at 2-3 weeks and 8.24±17.9.91 (normal) at 6 months after treatment. CFS was identified in 51.6% (32/62) before and in 45.2% (28/62) 6 months (p=0.293) after treatment. ST (p=0.014) grades improved; OSM grades mild worsened (p<0.001); TMH, NIBUT and LAMG grades did not modify 6 months after treatment. No patient suffered any adverse effects.
conclusionIPL combined with LLL was effective and safe, improving the lipid layer thickness in MGD and decreasing the level of symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.